Cartesian Therapeutics Q2 2024 GAAP EPS $0.54 May Not Be Comparable To $(1.19) Estimate, Sales $33.445M May Not Be Comparable To $1.200M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cartesian Therapeutics reported Q2 2024 GAAP EPS of $0.54, which may not be comparable to the $(1.19) estimate. The company also reported sales of $33.445M, which may not be comparable to the $1.200M estimate.
August 08, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cartesian Therapeutics reported significantly better-than-expected Q2 2024 GAAP EPS of $0.54 compared to the $(1.19) estimate and sales of $33.445M compared to the $1.200M estimate.
The significant positive earnings surprise and much higher sales figures compared to estimates are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100